3C-AL
3C-AL, also known as 4-allyloxy-3,5-dimethoxyamphetamine or as α-methylallylescaline, is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine. It is the amphetamine analogue of allylescaline. The drug has a dose range of 15 to 30mg orally and a duration of 8 to 12hours. Its effects have been described as more visual than those of allylescaline. The drug is a potent partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets. The chemical synthesis of 3C-AL has been described. 3C-AL was described by Alexander Shulgin in his 1991 book PiHKAL, but he did not synthesize or test 3C-AL. Instead, Daniel Trachsel synthesized 3C-AL in 2002 and described its properties and effects in 2013. The pharmacology of 3C-AL was studied in greater detail in 2021. It is a controlled substance in Canada under phenethylamine blanket-ban language.